Gossamer Bio, Inc. — Form SCHEDULE 13D/A
Filed October 29, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 28/100
What the filing says
Two D.E. Shaw entities—Cogence and Valence Portfolios—sold approximately 32,000 common shares of Gossamer Bio between October 9–29, 2026, at prices ranging from $8.48 to $10.80 per share, totaling ~$303M in gross proceeds. The sales represent a systematic liquidation via multiple tranches. This Schedule 13D/A amendment reports these transactions by the principal shareholder entities of the company.
Why this rating
Share sales by controlling shareholder signal reduced conviction; proceeds (~$303M) far exceed company market cap ($271M), but are D.E. Shaw portfolio reallocation, not company-specific negative. Routine insider disclosure.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.